悦康药业：子公司注射用YKYY031获药物临床试验批准通知书

Core Viewpoint - Yuyuan Pharmaceutical (688658.SH) announced that its wholly-owned subsidiary, Beijing Yuyuan Ketech Pharmaceutical Technology Co., Ltd., and Hangzhou Tianlong Pharmaceutical Co., Ltd. have received approval from the National Medical Products Administration for the clinical trial of injectable YKYY031, a universal mRNA tumor vaccine intended for the treatment of advanced solid tumors [2]. Group 1 - Yuyuan Pharmaceutical's subsidiary has obtained a clinical trial approval for YKYY031 [2] - YKYY031 is designed as a universal mRNA vaccine targeting advanced solid tumors [2]